On : 10 july 2025
CAGR Value :
• The global peripheral decarboxylase inhibitors market size was valued at USD 1.52 billion in 2024. The market is projected to grow from USD 1.62 billion in 2025 to USD 2.21 billion by 2032, exhibiting a CAGR of 5.5% during the forecast period.
Email: help@intelmarketresearch.com +91 9169164321
• Peripheral Decarboxylase Inhibitors (PDIs) are a specialized class of therapeutics that selectively inhibit the enzyme aromatic L-amino acid decarboxylase (AADC) in peripheral tissues. These drugs play a critical role in Parkinson's disease treatment by preventing premature conversion of levodopa to dopamine outside the central nervous system, thereby enhancing therapeutic efficacy while minimizing adverse effects. The primary PDIs in clinical use include carbidopa and benserazide, which are typically coadministered with levodopa in fixed-dose combinations.
Email: help@intelmarketresearch.com +91 9169164321
By Types
Hospital
Retail Pharmacy
Long-term care facilities
Others
Key Players :
•AbbVie Inc. (U.S.)
•Roche Holding AG (Switzerland)
•Teva Pharmaceutical Industries (Israel)
•Amneal Pharmaceuticals (U.S.)
•Roemmers SAICF (Argentina)
•Organon Pharma (U.S.)
Email: help@intelmarketresearch.com +91 9169164321
